Personalized mRNA Vaccine Reduces Melanoma Recurrence Risk by 42%

• A personalized mRNA cancer vaccine reduced melanoma recurrence risk by 42% compared to standard treatment.
• The vaccine was developed by Moderna and Merck and tested in a large clinical trial.
• Patients who received the vaccine lived significantly longer without their cancer returning.
• Moderna CEO Stephane Bancel said the findings herald a new chapter in treating cancer.
• The results are considered an important advance for the treatment of melanoma by oncologists.